What GHRP-2 is
Growth hormone-releasing peptide-2 (GHRP-2, also called pralmorelin) is a synthetic hexapeptide and ghrelin-receptor agonist. It contains non-natural amino-acid chemistry and stimulates pituitary growth-hormone release; it is not growth hormone itself.
GHRP-2 has been studied as a provocative endocrine test, including use in Japan, but no GHRP-2 drug product is FDA-approved in the United States. A foreign diagnostic product, a research reagent, a compounded nasal product, and an injectable online vial are not interchangeable.
Human studies show a hormone response—not clinical enhancement
In a diagnostic study of 77 healthy people and 58 patients with severe growth-hormone deficiency, intravenous GHRP-2 produced a reproducible growth-hormone response that separated the groups under that study’s assay and conditions.[1] A 15-patient pilot also measured ACTH and cortisol responses, showing that GHRP-2 is not selective for the growth-hormone axis.[2]
These studies assessed short-term biomarkers in controlled clinical tests. They did not demonstrate increased strength, muscle, fat loss, recovery, sleep quality, anti-aging benefit, or improved health in healthy users. Diagnostic thresholds also depend on assay, population, protocol, and route and cannot be repurposed as a wellness regimen.
Endocrine effects are broader than GH
A small study in six young and six older adults found intravenous GHRP-2 increased growth hormone and also prolactin, ACTH, and cortisol.[3] Ghrelin-receptor activation can also affect appetite and glucose regulation. A larger hormone peak is not automatically desirable and does not establish a favorable long-term benefit-risk profile.
Claims that GHRP-2 is a selective, predictable, or low-risk substitute for approved growth-hormone treatment are therefore unsupported. Approved replacement therapy is diagnosis- and product-specific.
FDA identifies significant compounding concerns
FDA places GHRP-2 for injectable and nasal administration in category 2 of the 503B interim compounding policy. The agency cites immunogenicity risk from aggregation and peptide-related impurities, complexity from an unnatural amino acid, and reports including increased insulin requirements, infection, pancreatitis, and deaths in critically ill study subjects; FDA notes that causality has not been established.[4]
Those reports do not prove that GHRP-2 caused every event, but they contradict the idea that long-term or self-directed use has an established safety profile. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[5]
Regulatory and sport status
No approved U.S. indication or dose exists for GHRP-2. It is also prohibited in sport as a growth-hormone-releasing factor under the current World Anti-Doping Agency list.[6] Teloryx therefore withholds dosing, nasal, injection, cycling, and combination protocols.